The HLA-B*2705 peptidome

Arthritis and Rheumatism

Volumn 62, Issue 2, 2010, Pages 420-429

  Dror, Lilach Ben ^a   Barnea, Eilon ^a   Beer, Ilan ^b   Mann, Matthias ^c   Admon, Arie ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b IBM HAIFA RESEARCH LAB   (Israel)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HLA B ANTIGEN; HLA B27 ANTIGEN; HLA B2705; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; EPITOPE; HLA B 2705 ANTIGEN; HLA-B 2705 ANTIGEN; PEPTIDE FRAGMENT;

ALLELE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; CAPILLARY CHROMATOGRAPHY; CARTILAGE; CARTILAGE CELL; CONSENSUS SEQUENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC RECOMBINATION; HELA CELL; HUMAN; HUMAN CELL; INFECTIOUS ARTHRITIS; PRIORITY JOURNAL; PROTEIN MOTIF; SPONDYLOARTHRITIDES; SPONDYLOSIS; TANDEM MASS SPECTROMETRY; CELL LINE; CHEMISTRY; CHONDROSARCOMA; CYTOLOGY; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MOLECULAR MIMICRY; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SPONDYLARTHRITIS; T LYMPHOCYTE;

ANTIGENS, BACTERIAL; BACTERIAL INFECTIONS; CARTILAGE; CELL LINE, TRANSFORMED; CHONDROCYTES; CHONDROSARCOMA; EPITOPES; HELA CELLS; HLA-B27 ANTIGEN; HUMANS; MOLECULAR MIMICRY; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; SPONDYLARTHRITIS; T-LYMPHOCYTES;

EID: 75749136956     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27257     Document Type: Article

References (50)

1. Benjamin R, Parham P. Guilt by association: HLA-B27 and ankylosing spondylitis. Immunol Today 1990;11:137-42.
2. Lopez de Castro JA. HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol Lett 2007;108:27-33.
3. Sheehan NJ. The ramifications of HLA-B27. J R Soc Med 2004;97:10-4.
4. Taurog JD. The mystery of HLA-B27: if it isn't one thing, it's another [editorial]. Arthritis Rheum 2007;56:2478-81.
5. Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, Lopez de Castro JA. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002;277:37573-81.
6. Wildner G, Diedrichs-Mohring M, Thurau SR. Induction of arthritis and uveitis in Lewis rats by antigenic mimicry of peptides from HLA-B27 and cytokeratin. Eur J Immunol 2002;32:299-306.
7. Ugrinovic S, Mertz A, Wu P, Braun J, Sieper J. A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. J Immunol 1997;159:5715-23.
8. Cragnolini JJ, Lopez de Castro JA. Identification of endogenously presented peptides from Chlamydia trachomatis with high homology to human proteins and to a natural self-ligand of HLA-B27. Mol Cell Proteomics 2008;7:170-80.
9. Karunakaran KP, Rey-Ladino J, Stoynov N, Berg K, Shen C, Jiang X, et al. Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia. J Immunol 2008; 180:2459-65.
10. Pfeifer JD, Wick MJ, Roberts RL, Findlay K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993;361:359-62.
11. Zenewicz LA, Foulds KE, Jiang J, Fan X, Shen H. Nonsecreted bacterial proteins induce recall CD8 T cell responses but do not serve as protective antigens. J Immunol 2002;169:5805-12.
12. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993;342:646-50.
13. Boyle LH, Goodall JC, Gaston JS. The recognition of abnormal forms of HLA-B27 by CD4+ T cells. Curr Mol Med 2004;4:51-8.
14. Tian J, Olcott A, Hanssen L, Zekzer D, Kaufman DL. Antigenbased immunotherapy for autoimmune disease: from animal models to humans? Immunol Today 1999;20:190-5.
15. Thurau SR, Fricke H, Burchardi C, Diedrichs-Mohring M, Wildner G. Long-term follow-up of oral tolerance induction with HLA-peptide B27PD in patients with uveitis. Ann N Y Acad Sci 2004;1029:408-12.
16. Sharma SD, Nag B, Su XM, Green D, Spack E, Clark BR, et al. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes. Proc Natl Acad Sci U S A 1991;88:11465-9.
17. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992;70:1035-48.
18. Apostolopoulos V, Lazoura E. Noncanonical peptides in complex with MHC class I. Expert Rev Vaccines 2004;3:151-62.
19. Burrows SR, Rossjohn J, McCluskey J. Have we cut ourselves too short in mapping CTL epitopes? Trends Immunol 2006;27:11-6.
20. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
21. Kuipers JG, Bialowons A, Dollmann P, Jendro MC, Wagener N, Rebmann V, et al. The genetically-engineered secretory B27/Q10 chimeric molecule inhibits HLA-B27 restricted alloreactive T-lymphocytes. Clin Exp Rheumatol 2002;20:455-62.
22. Barnea E, Beer I, Patoka R, Ziv T, Kessler O, Tzehoval E, et al. Analysis of endogenous peptides bound by soluble MHC class I molecules: a novel approach for identifying tumor-specific antigens. Eur J Immunol 2002;32:213-22.
23. Ishihama Y, Rappsilber J, Andersen JS, Mann M. Microcolumns with self-assembled particle frits for proteomics. J Chromatogr A 2002;979:233-9.
24. Beer I, Barnea E, Ziv T, Admon A. Improving large-scale proteomics by clustering of mass spectrometry data. Proteomics 2004;4:950-60.
25. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
26. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 2002;1:376-86.
27. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 2006;7:952-8.
28. Milner E, Barnea E, Beer I, Admon A. The turnover kinetics of major histocompatibility complex peptides of human cancer cells. Mol Cell Proteomics 2006;5:357-65.
29. Lopez de Castro JA, Alvarez I, Marcilla M, Paradela A, Ramos M, Sesma L, et al. HLA-B27: a registry of constitutive peptide ligands. Tissue Antigens 2004;63:424-45.
30. Colmegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev 2004;17:348-69.
31. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9.
32. Yamaguchi A, Tsuchiya N, Mitsui H, Shiota M, Ogawa A, Tokunaga K, et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients: evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum 1995;38:1672-7.
33. Herberts CA, Neijssen JJ, de Haan J, Janssen L, Drijfhout JW, Reits EA, et al. HLA-B27 acquires many N-terminal dibasic peptides: coupling cytosolic peptide stability to antigen presentation. J Immunol 2006;176:2697-701.
34. Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol 2004;5:670-7.
35. Urban RG, Chicz RM, Lane WS, Strominger JL, Rehm A, Kenter MJ, et al. A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci U S A 1994;91:1534-8.
36. 2-microglobulin-free heavy chains of HLA-B2705 on the cell surface. J Immunol 2002;169:4379-87.
37. Guo HC, Jardetzky TS, Garrett TP, Lane WS, Strominger JL, Wiley DC. Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature 1992;360:364-6.
38. Silver ML, Guo HC, Strominger JL, Wiley DC. Atomic structure of a human MHC molecule presenting an influenza virus peptide. Nature 1992;360:367-9.
39. Wilson IA, Fremont DH. Structural analysis of MHC class I molecules with bound peptide antigens. Semin Immunol 1993;5: 75-80.
40. Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum 2005;52:892-901.
41. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000;141:3478-84.
42. Kirsch T. Annexins - their role in cartilage mineralization. Front Biosci 2005;10:576-81.
43. McKie N, Edwards T, Dallas DJ, Houghton A, Stringer B, Graham R, et al. Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. Biochem Biophys Res Commun 1997;230:335-9.
44. Kim TH, Uhm WS, Inman RD. Pathogenesis of ankylosing spondylitis and reactive arthritis. Curr Opin Rheumatol 2005;17: 400-5.
45. Fielder M, Pirt SJ, Tarpey I, Wilson C, Cunningham P, Ettelaie C, et al. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett 1995;369:243-8.
46. Braun J, Khan MA, Sieper J. Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann Rheum Dis 2000;59:985-94.
47. Frauendorf E, von Goessel H, May E, Marker-Hermann E. HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clin Exp Immunol 2003;134:351-9.
48. Paradela A, Garcia-Peydro M, Vazquez J, Rognan D, Lopez de Castro JA. The same natural ligand is involved in allorecognition of multiple HLA-B27 subtypes by a single T cell clone: role of peptide and the MHC molecule in alloreactivity. J Immunol 1998;161:5481-90.
49. Lo WF, Woods AS, DeCloux A, Cotter RJ, Metcalf ES, Soloski MJ. Molecular mimicry mediated by MHC class Ib molecules after infection with gram-negative pathogens. Nat Med 2000;6:215-8.
50. Jiang X, Gregory SH, Wing EJ. Immune CD8+ T lymphocytes lyse Listeria monocytogenes-infected hepatocytes by a classical MHC class I-restricted mechanism. J Immunol 1997;158:287-93.